<b><i>Background:</i></b> Neonatal thrombosis is a frequently encountered complication in neonatal intensive care unit. Dalteparin can be used to treat newborn infants. <b><i>Objectives:</i></b> In this study, we evaluate the current recommended starting dose of 129 ± 43 U/kg/24 h, hypothesizing that too low reach therapeutic anti-Xa levels. <b...

The interaction between trypsin, a prototype S1 serine protease, with heparin and its low molecular weight derivative dalteparin were investigated. Direct inhibition of the proteolytic activity of trypsin by heparin and dalteparin, used in concentrations typical for their clinical application, was detected. The half-maximum inhibition of the trypsin activity was achieved at 15.25±1.22 μg/mL for...

BACKGROUND The use of low-molecular weight heparin (LMWH) during percutaneous coronary intervention (PCI) has been limited by the presumed inability to monitor its anticoagulant effect using bedside assays. OBJECTIVES This study was designed to compare the dose-response of enoxaparin, dalteparin and unfractionated heparin (UFH) on the activated clotting time (ACT), and to determine whether th...

BACKGROUND: In recent years, the use of low molecular weight heparins such as dalteparin has become attractive because of their ease of administration and superiority in preventing venous thromboembolism (VTE) compared with traditional agents. The primary purpose of our study was to evaluate the impact of dalteparin use on blood loss and transfusion rates in patients undergoing primary total jo...

BACKGROUND Dalteparin, a low-molecular-weight heparin, has anticoagulant and anti-angiogenic activity. This study investigated whether dalteparin reduced coronary artery lesion (CAL) prevalence, and resistance to intravenous immunoglobulin (IVIG) therapy in Kawasaki disease (KD). METHODS This retrospective study comprised two parts. In the first cohort, 126 patients with KD (68 male, 58 femal...

Traumatic brain injury (TBI) patients are known to be at high risk for venous thromboembolic events (VTEs). The Brain Trauma Foundation Guidelines (2007) state that low-molecular-weight heparin or unfractionated heparin should be used to prevent VTE complications, but suggest that there is an increased risk of expansion of intracranial hemorrhages (ICH) with VTE prophylaxis. In addition, it is ...

OBJECTIVE Chronic foot ulcers are a common, severe, and expensive complication threatening life and limb in patients with diabetes. The aim of the present study was to investigate the effect of dalteparin on ulcer outcome in patients with diabetes, peripheral arterial occlusive disease, and chronic foot ulcers. RESEARCH DESIGN AND METHODS A total of 87 patients were investigated in a prospect...

BACKGROUND The activated clotting time (ACT) has been reported to be sensitive to the anticoagulant activity of the low-molecular weight heparin dalteparin following intravenous (IV) administration. OBJECTIVE To evaluate the feasibility of an ACT-guided dalteparin dose adjustment strategy during percutaneous coronary intervention (PCI). METHODS This was a retrospective study of 104 consecut...

Introduction: Hepcidin is the principal modulator of systemic iron metabolism, and its role in the brain has been clarified recently. Studies have shown hepcidin plays an important role for in neuronal iron load and inflammation. This is of significance because neuronal iron load and inflammation are pathophysiological processes that have been highly linked to neurodegeneration. Moreover, the a...